Randomized controlled trials in systemic lupus erythematosus: What has been done and what do we need to do?

Lupus

Volumn 13, Issue 5, 2004, Pages 398-405

  Schiffenbauer, Joel ^a,c   Simon, L S ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CDER   (United States)

Author keywords

Disease activity indices (DAIs); Flare; Health related quality of life (HRQOL); Lupus; Noninferiority trials; Randomized controlled trials (RCTs)

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX; DISEASE EXACERBATION; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 2942737087     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu1033oa     Document Type: Review

References (27)

1. Liang MH, Corzillius M, Bae S, Fortin P, Esdaile JM, Abrahamowicz M. A conceptual framework for clinical trials in SLE and other multisystem diseases. Lupus 1999; 8: 570-580.
2. Corzillius M, Bae S. Methodological issues of corticocorticosteroid use in SLE clinical trials. Lupus 1999; 8: 692-697.
3. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685-691.
4. Moher D, Schulz K, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. Lancet 2001; 357: 1191-1194.
5. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Lupus 2000; 9: 322-327.
6. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in SLE. J Rheumatol 1999; 26: 490-497.
7. Corzillius M, Fortin P, Stucki G. Responsiveness and sensitivity to change in ALE disease activity measures. Lupus 1999; 8: 655-659.
8. Fortin P, Abrahamowicz M, Clarke A et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000; 27: 1421-1428.
9. Fortin P, Abrahamowicz M, Neville C et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998; 7: 101-107.
10. Gordon C, Sutcliffe N, Skan J, Stoll J, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003; 42: 1-8.
11. Hay E, Bacon P, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in SLE. Q J Med 1993; 86: 447-458.
12. Merril J. Measuring disease activity in systemic lupus: progress and problems. J Rheumatol 2002; 29: 2350-2358.
13. Alarcon-Segovia D, Tumlin J, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double blind, placebo controlled study. Arth Rheum 2003; 48: 442-454.
14. Schiffenbauer J, Chakravarty E, Strand V. Evidence based treatment of systemic lupus erythematosus. In Tuguell P, Shea B, Boers M, Wells G eds. Evidence based rheumatology. London: BMJ Publishing Group, 2004: 97-127.
15. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
16. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy. Arth Rheum 2002; 46: 995-1002.
17. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
18. Rahman P, Goladman D, Urowitz M, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in SLE. Lupus 2001; 10: 93-96.
19. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the SLICC/ACR damage index for SLE. Arth Rheum 1996; 39: 363-369.
20. Wang C, Mayo N, Fortin P. The relationship between health related quality of life and disease activity and damage in SLE. J Rheumatol 2001; 28: 525-532.
21. Stoll T, Gordon C, Seifert B et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with SLE. J Rheumatol 1997; 24: 1608-1614.
22. Gordon C, Clarke A. Quality of life and economic evaluation in SLE clinical trials. Lupus 1999; 8: 645-654.
23. Thumbo J, Fong K, Ng T et al. Validity of the MOS SF-36 for quality of life assessment of patients with SLE in Singapore. J Rheumatol 1999; 26: 97-102.
24. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New Engl J Med 1991; 324: 150-154.
25. Steinberg AD, Kaltreider HB, Staples PJ, Goetzel EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Int Med 1971; 75: 165-171.
26. Petri MA, Lahita RG, van Vollenhoven RF et al. Effects of prasterone on corticosteroid requirement of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002; 46: 1820-1829.
27. Houssiau F, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arth Rheum 2002; 46: 2121-2131.